AADI News and Press, Aadi Bioscience Inc. From 11/03/22

Aadi Bioscience to Present at Upcoming Investor Conferences PR Newswire LOS ANGELES , Nov. 3, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision thera...

Preclinical data showed that combining Aadi Bioscience's ( NASDAQ: AADI ) Fyarro (nab-sirolimus) with a KRAS inhibitor led to improved anti-tumor activity . KRAS is frequently mutated in non-small cell lung cancer (NSCLC) and other tumors. The company's resear...

Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium PR Newswire Poster presentation scheduled for October 27, 2022 LOS ANGELES , Oct. 12, 2022 /PRNews...

Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C] Mutation PR Newswire SAN DIEGO and LOS ANGELES , Oct....

The following slide deck was published by Aadi Bioscience, Inc. in conjunction with this event. For further details see: Aadi Bioscience (AADI) Presents At Ladenburg Thalmann Healthcare Conference - Slideshow

Aadi Bioscience ( NASDAQ: AADI ) has entered into a securities purchase agreement with a new accredited investor and certain existing investors to issue and sell an aggregate of ~3.37M shares at a price of $12.50 per share, and pre-funded warrants to purchase up to an aggregat...

Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing PR Newswire LOS ANGELES , Sept. 22, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genet...

Summary Shares have lost half their value since reverse merger with Aerpio Pharmaceuticals. Aadi aims to deliver on the broad potential of mTOR inhibition via nab technology to achieve wide therapeutic index and greater target suppression. Registrational data for Fyarro in PEC...

Aadi Bioscience Announces Participation in Upcoming September Investor Conferences PR Newswire LOS ANGELES , Sept. 1, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commerc...

Aadi Bioscience, Inc. (AADI) Q2 2022 Earnings Conference Call August 10, 2022, 08:30 AM ET Company Participants Marcy Graham - SVP of IR and Corporate Communications Neil Desai - President and CEO Brendan Delaney - COO Loretta Itri - Chief Medical Officer ...